Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 813

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 813
---
***].
“Licensed Know-How” shall include, but is not limited to, [***].

1.43 “Licensed Platform Patents” means all Patents Controlled by WuXi Biologics or any of its Affiliates, as of
the Effective Date or at any time during the Term, [***].

1.44 “Licensed Product” means any pharmaceutical
product(s) containing a Licensed ADC as an active pharmaceutical ingredient, including all forms, formulations, modes of administration, presentations, and dosages thereof.

1.45 “Licensed Target” means, individually, each of (a) MUC16, (b) PTK7 and (c) SEZ6; and
collectively, such targets the “Licensed Targets”.

1.46 “Major Market” means,
individually, each of [***]; and collectively, such countries the “Major Markets”.

1.47 “Manufacture” means, together with all correlative meanings, with respect to a product, all activities
related to the production of a Licensed ADC or a Licensed Product, including those manufacturing activities involved in or relating to (a) manufacturing process development, (b) CMC activities including analytical development and
qualification, formulation development, solubility testing, bulk drug substance manufacturing, stability testing and scale-up activities, bulk drug product manufacturing and stability testing, (c) quality
assurance and quality control activities including validation testing, qualification and audit of clinical and commercial manufacturing facilities, and (d) in the case of either a clinical or commercial supply of such product or supply of such
product for any non-clinical study, the manufacturing, processing, formulating, packaging, labeling, holding, quality control testing and release of such product.

1.48 “Marketing Approval” shall mean approval of a Marketing Approval Application by the applicable Regulatory
Authority.

1.49 “Marketing Approval Application” or “MAA” means an application requesting
Regulatory Approval for the marketing and/or commercialization of a Licensed Product for a particular Indication in a particular jurisdiction filed with the relevant Regulatory Authorities in such jurisdiction, including with respect to the U.S., a
Biologics License Application submitted to the FDA pursuant to Section 351(a) of the Public Health Service Act (“BLA”)or a New Drug Application (as more fully defined in 21 CFR 314.5, et seq.) filed with the FDA, or any
successor application thereto in the U.S. (“NDA”). Where used in this Agreement